A Phase I, Single Center, Open-Label, Randomized, Single Dose Cross-Over Study in Healthy Male Subjects to Investigate the Bioequivalence and Tolerability of Liquid and Reconstituted Lyophilized Subcutaneous Formulations of Caplacizumab.

Trial Profile

A Phase I, Single Center, Open-Label, Randomized, Single Dose Cross-Over Study in Healthy Male Subjects to Investigate the Bioequivalence and Tolerability of Liquid and Reconstituted Lyophilized Subcutaneous Formulations of Caplacizumab.

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Nov 2014

At a glance

  • Drugs Caplacizumab (Primary) ; Caplacizumab
  • Indications Thrombotic thrombocytopenic purpura
  • Focus Pharmacokinetics
  • Sponsors Ablynx
  • Most Recent Events

    • 13 Nov 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 17 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top